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INTRODUCTION
Despite the reduction in the incidence of gastric cancer in
most areas of the world, gastric cancer remains the second
leading cause of cancer death worldwide (1, 2). Gastric can-
cer can be cured by complete surgical resection. Unfortunate-
ly, at the time of presentation patients often have advanced,
unresectable disease, and therefore, become candidates for
systemic chemotherapy. Based on the evidence of randomized
chemotherapy trials versus best supportive care, chemothera-
py confers benefits in quality of life and survival (3-5). How-
ever, there is no standard chemotherapy for gastric cancer (6).
Heptaplatin, cis-malonatol [(4R, 5R)-4,5-bis(aminome-
thyl)-2-isopropyl-1,3-dioxolane] platinum(II) (SKI-2053R,
Sunpla
�, SK Chemicals, Kyungki-do, Korea) is a new drug of
platinum derivatives. In vitro studies have shown that it has
high antitumor activity against various cancer cell lines (7-9).
A phase II study found that this agent had a response rate of
17% as a single agent and tolerable toxicity in advanced gas-
tric cancer (10). Therefore, we conducted a study to evaluate
the efficacy and toxicity of a combination of 5-fluorouracil (5-
FU) and heptaplatin in patients with advanced gastric cancer.
MATERIALS AND METHODS
Forty-seven patients were enrolled between October 2001
and February 2003.
Patient selection
Patients with histologically confirmed, metastatic adeno-
carcinoma of the stomach were eligible. Recurred disease after
gastric resection cases was also allowed but prior chemothera-
py or radiotherapy was not permitted. At entry, patients were
required to have measurable disease [i.e. with at least one dia-
meter ≥2 cm, as assessed by physical or radiography exam-
ination including chest radiography or computed tomogra-
phy scan] (11). The eligibility criteria were as follows: age
≤70 yr; performance status (PS) ≤3 according to the East-
ern Cooperative Oncology Group (ECOG) criteria; adequate
bone marrow function (absolute neutrophil count ≥1,500/
L, platelet count ≥100,000/ L), adequate hepatic func-
tion (bilirubin level <two times the upper normal limit, AST
and/or ALT <three times the upper normal limit) and ade-
quate renal function (creatinine <1.5 mg/dL). Patients with
uncontrolled infections, medical instability, pregnancy, or
brain metastases were excluded from the study. The protocol
was approved by the institutional review board of the Ulsan
University Hospital, and all patients gave written informed
consent.
Treatment Schedule 
5-FU was administered over 120 hr of continuous intra-
venous infusion from day 1 to 5, at a daily dose of 1,000
mg/m2 and heptaplatin was administered over 1 hr by intra-
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Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as
First-line Treatment in Patients with Advanced Gastric Cancer
Heptaplatin is a recently developed platinum derivative. This agent has been report-
ed to have a response rate of 17% as a single agent, and tolerable toxicity in the
treatment of advanced gastric cancer. The aim of this study was to evaluate the
efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in
patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients
with advanced or recurred gastric cancer were recruited. 5-FU was administered
over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of
1,000 mg/m
2 and heptaplatin was administered over 1 hr by intravenous infusion
on day 1 at 400 mg/m
2, and this cycle was repeated every 4 weeks. The response
rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to
2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months)
and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was
proteinuria. Toxicities were generally mild and reversible. This study demonstrates
that the combination of 5-FU/heptaplatin combination is less active but tolerated in
patients with advance gastric cancer.
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venous infusion on day 1 at a dose of 400 mg/m2, and this
cycle was repeated every 4 weeks. Prehydration with 1.5 L
of normal saline mixed with 20 mEq KCl and 8 mEq MgSO4
was infused prior to the heptaplatin administration and an
additional 1.5 L was given after administration. Ondansetron
and metoclopropamide were given as an antiemetic prophy-
laxis. The dose of 5-FU was reduced by 25% for ≥grade 3
toxicities (except alopecia) and cycles were delayed until re-
solved to grade 2 toxicity. The dose of heptaplatin was reduced
by 50% if the serum creatinine was between 1.6 and 2.5 mg/
dL, and was omitted if the serum creatinine still remained
greater than 2.5 mg/dL after a delay of 1 week.
Pretreatment and follow-up studies 
Before entry onto the study, all patients were required to
have a physical examination, chest radiography, abdomen
computed tomographic scan, complete blood counts (CBC),
biochemical tests, urine analysis with microscopy and an
ECG. A physical examination, CBC, biochemical tests and
urine analysis with microscopy were checked before each
cycle and days 14 after each cycle of therapy.
Response and Toxicity Evaluation
Patients who received at least two cycles of treatment were
assessable for response unless they had definitive evidence of
progression after the first cycle. Patients who had received at
least one cycle of treatment were assessed for toxicity. Res-
ponses were graded according to the RECIST criteria (11).
Complete remission (CR) was defined as the disappearance
of all known lesions, the absence of any new lesions and the
normalization of tumor markers for at least 4 weeks. Partial
remission (PR) was defined as a decrease of 30% or greater
in the sum of the longest diameters of the target lesions from
baseline, non-progressive disease in the non-target lesion, and
no new lesions. Progressive disease (PD) was defined as at
least a 20% increase in the sum of the longest diameters of
the target lesions or the appearance of new lesions. Stable
disease (SD) was defined as an insufficient decrease in size in
tumor to qualify for PR or an insufficient increase in size to
qualify for PD. Toxicity grading was performed in accor-
dance with WHO toxicity criteria.
Survival curves were constructed using the Kaplan-Meier
methods and compared using the log-rank test. Analysis was
performed using the SPSS 8.0 system (SPSS, Inc, Chicago,
IL, U.S.A.). A p value of less than 0.05 was considered sta-
tistically significant.
RESULTS
The patient characteristics are listed in Table 1. Median
patients age was 53 yr (range, 22-70). Thirty-nine patients
(83%) had metastatic disease and 8 patients (13%) had re-
curred disease after primary curative resection. All patients
received at least one cycle of chemotherapy.
Treatment, response and survival
A total of 120 cycles was administered. The median number
of cycles per patient was two (range, 1-9). Seventeen patients
(36%) were considered non-assessable for response: 3 lost to
follow up, 5 withdrawn voluntarily, 6 had chemotherapy-
induced toxicity, including 5 with nausea and vomiting and
1 with renal impairment, and there were 3 early deaths due
to gastric bleeding. Thus, a total of 30 patients (64%) were
assessable for response.
Partial responses were reported in 10 patients, resulting in
an overall response rate of 21% in the intension-to-treat popu-
lation (Table 2). There was no case of CR, 17% achieved SD
and 26% PD. Median duration of response was 3.6 months
(95% confidence interval (CI), 3.4 to 3.9 months) (Fig. 1A).
Median progression-free survival was 1.9 months (95% CI,
1.6 to 2.2 months) (Fig. 1B). Median overall survival was 6.2
No. of patients %
Sex
Male 28 60
Female 19 40
Median age (yr) 53
Range 22-70
Performance status
ECOG
0 2 4.3
1 19  40.4
2 16  34
3 10  21.3
Metastatic sites
Lymph nodes 18  30
Liver 16 27
Peritoneal 12 20
Ovary 3 5
Pancreas 3 5
Bone 3 5
Colon 2 3
Skin 2 3
Lung 1 2
Table 1. Patient characteristics (n=47)
No. of patients (n=47) % 
CR 0 0
PR 10 21
SD 8 17
PD 12 26
NE 17 36
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; NE, not evaluable.
*Intention-to-treat analysis.
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months (95% CI, 4 to 8.4 months), and the 1 yr survival rate
for all patients was 29% (Fig. 2A). Patients with a PS of 0
or 1 showed significantly better survival than those with a
PS of 2 or 3 (1-yr survival rate: 54% vs. 0%, p=0.001) (Fig.
2B). However, ages, sex, and metastatic sites did not affect
overall survival.
Toxicities
The hematologic and nonhematologic toxicities were evalu-
ated in 44 patients, and are shown in Table 3. Hematologic
toxicities were mild. Neutropenia (grade 3-4) and anemia
(grade 3-4) appeared in 19% and 6% of the patients, respec-
tively. 4% of the patients experienced grade 3 thrombocytope-
nia. Nonhematologic toxicities were also mild. However, nau-
sea and vomiting occurred frequently (64%) and grade 3 toxi-
city occurred in 6% of patients. Azotemia was observed in
34% of the patients with 2% (grade 3). Proteinuria appeared
frequently (65%) and 8% of the patients showed grade 3-4
Grade (%)
123 4
Toxicity
(WHO criteria)
Oral mucositis 2 2 - -
Nausea/vomiting 30 28 6 -
Leucopenia 15 21 6 -
Neutropenia 11 11 13 6
Anemia 13 26 4 2
Thrombocytopenia 2 2 4 -
AST/ALT 23 6 2 -
A L P 924-
Cr 30 2 2 -
Proteinuria 17 40 6 2
Fever 2 - - -
Table 3. Frequency of toxicity
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Fig. 1. (A) Duration of response, (B) Progression free survival.
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Fig. 2. (A) Overall survival, (B) Effect of performance status on overall survival.
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toxicity. Observed renal insufficiency was reversible.
DISCUSSION
This study based on a continuous infusion of 5-FU with
heptaplatin (FH) demonstrated a response rate of 21% in all
patients with advanced gastric cancer who had not previous-
ly received chemotherapy. Median progression-free survival
and overall survival were 1.9 months and 6.2 months, respec-
tively. Even though no standard regimens have yet been estab-
lished, infusional 5-FU-based regimens have shown promise
in combinations in the treatment of gastric cancer (12-14).
Despite the activity of cisplatin as a single agent in first-line
chemotherapy for gastric cancer has not been well defined.
Nevertheless, cisplatin is one of the most common agents
used for the treatment of gastric cancer (12-17). In particu-
lar, the regimen of a continuous 5-day infusion of 5-FU with
cisplatin (FP) produced response rates of 41% and 43%, with
a median survival of 10.6 and 9 months in nonrandomized
phase II studies (12, 13). Heptaplatin is a recently developed
platinum derivative. This agent had shown a response rate
of 17% as a single agent and tolerable toxicity in the treat-
ment of advanced gastric cancer (10). 
In the present study, the FH regimen showed inferior results
in terms of response rate and survival when compared with
the two studies. Otherwise, the FH regimen showed favor-
able profiles in terms of toxicities. Firstly, the hematologic
toxicities of the FH regimen were similar to those found in
the two trials with the FP regimen. The most common hema-
tologic toxicity was anemia. Grade 3-4 anemia and grade 3-
4 neutropenia occurred in 6% and 19% of patients, respec-
tively. Secondly, gastrointestinal toxicities of the FH regimen
were mild. Grade 3 nausea and vomiting only occurred in
6% of patients. Otherwise, 22% and 36.5% of patients had
grade 3-4 nausea and vomiting in the two trials with FP regi-
men. Azotemia was also mild with 4% of patients having
grade 2-3 toxicities, but proteinuria was frequent. Protein-
uria was already found to be the most remarkable toxicity of
the FH regimen (10, 18), 65% of patients had proteinuria
with 8% of patients having grade 3-4 toxicities. A phase III
study, which compared the toxicity of heptaplain and cisplatin
found that nephrotoxicity was more severe in patients treat-
ed with heptaplatin than in those treated with cisplatin (18).
Further efforts to detect and minimize the nephrotoxicity of
heptaplatin seem to be warranted.
One of the limitations in this study is that 36% of patients
were non-assessable for response. So, the result of this study
do not allow a conclusion to be drawn on difference between
the FH and the FP regimens in terms of efficacy or toxicity
for the treatment of advanced gastric cancer. The Korean
Cancer Study Group (KCSG) has initiated a randomized
phase III study in patients with advanced gastric cancer, which
incorporates a comparison between FP and FH.
In conclusion, our study shows that the 5-FU/heptaplatin
combination is less active but tolerable by patients with ad-
vanced gastric cancer.
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